« Return to News | Clinical Intelligence

Circadian launches phase I cancer trial

Monday, January 9, 2012 01:59 PM

Circadian Technologies, a biologic drug developer, has launched the first phase I clinical trial of VGX-100, its fully human monoclonal antibody against the human VEGF-C protein.

The study will examine the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumors. VGX-100 will be administered both as monotherapy, as well as in combination with other anti-angiogenic agents.

"We are extremely proud to have completed the translation of VGX-100 from early discovery to the clinical development stage,” said Robert Klupacs, CEO of Circadian. “We are committed to improving outcomes for patients suffering from cancer, and believe that VGX-100, especially when combined with existing therapies, could make a significant difference.”

Results are expected to be available in the second half of 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.